Acadia Pharma (ACAD) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
May 5, 2016 4:07 PM EDTSAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2016.
We are very excited about the recent FDA approval of NUPLAZID, the first and only drug approved for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis, said Steve Davis, ACADIAs President and Chief Executive Officer. Parkinsons psychosis tends to strike in the more advanced stages of... More
